SCHEMBL29378010

SCHEMBL29378010

Cc1cncc2cccc(S(=O)(=O)N3CCCNC[C@@H]3C)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 12/20 1.00
ROCK1 Q13464 11/20 1.00
PRKACA P17612 5/20 1.00
PRKCD Q05655 5/20 1.00
PRKD3 O94806 4/20 1.00
PRKCZ Q05513 4/20 1.00
PRKACG P22612 4/20 1.00
PRKACB P22694 4/20 1.00
PKN2 Q16513 3/20 1.00
AURKB Q96GD4 3/20 1.00
PRKD2 Q9BZL6 3/20 1.00
PLK4 O00444 2/20 1.00
MARK3 P27448 2/20 1.00
PRKAA1 Q13131 2/20 1.00
MARK2 Q7KZI7 2/20 1.00
MAP4K4 O95819 2/20 1.00
CHEK2 O96017 2/20 1.00
AKT1 P31749 2/20 1.00
PRKX P51817 2/20 1.00
CDK5 Q00535 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29372951 1.00 ROCK2 (1.00) ROCK2ROCK1PRKACAPRKCDPRKD3
SCHEMBL6969527 1.00 ROCK2 (1.00) ROCK2ROCK1PRKACAPRKCDPRKD3
SCHEMBL226317 1.00 ROCK2 (1.00) ROCK2ROCK1PRKACAPRKCDPRKD3
SCHEMBL30069136 1.00 ROCK2 (1.00) ROCK2ROCK1PRKACAPRKCDPRKD3
SCHEMBL124161 1.00 ROCK2 (1.00) ROCK2ROCK1PRKACAPRKCDPRKD3
SCHEMBL29677841 1.00 ROCK2 (1.00) ROCK2ROCK1PRKACAPRKCDPRKD3
Hydrochloric Acid SCHEMBL2456059 0.99 ROCK2 (0.98) ROCK2ROCK1PRKACAPRKCDPRKD3
Hydrochloric Acid SCHEMBL507871 0.99 ROCK2 (0.98) ROCK2ROCK1PRKACAPRKCDPRKD3
Hydrochloric Acid SCHEMBL2461354 0.99 ROCK2 (0.98) ROCK2ROCK1PRKACAPRKCDPRKD3
Hydrochloric Acid SCHEMBL29781011 0.99 ROCK2 (0.98) ROCK2ROCK1PRKACAPRKCDPRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3843845-B1 INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA UNIV MASSACHUSETTS (US) 2026-03-11 EP claimed
US-20250017977-A1 HEPATOCYTES AND HEPATIC NON-PARENCHYMAL CELLS, AND METHODS FOR PREPARATION THEREOF THE UNIVERSITY OF TOKYO (JP) 2025-01-16 US claimed
WO-2024128696-A1 METHOD FOR INDUCING DIFFERENTIATION OF STEM CELLS INTO CORNEAL ENDOTHELIAL CELLS AND USE THEREOF 재단법인 아산사회복지재단 2024-06-20 WO claimed
US-20260009003-A1 MANUFACTURING OF THERAPEUTIC SATELLITE CELLS FOR TREATING MUSCULAR DYSTROPHY VITA THERAPEUTICS INC (US) 2026-01-08 US disclosed
US-20250179428-A1 METHOD FOR INDUCING DIFFERENTIATION OF CORNEAL EPITHELIAL CELLS FROM PLURIPOTENT STEM CELLS OSAKA UNIVERSITY (JP) 2025-06-05 US disclosed
US-12247219-B2 Method for inducing differentiation of corneal epithelial cells from pluripotent stem cells OSAKA UNIVERSITY (JP) 2025-03-11 US disclosed
CN-119546748-A Fibrin gel sheet for cell transplantation 千纸鹤治疗公司 2025-02-28 CN disclosed
US-20250017977-A1 HEPATOCYTES AND HEPATIC NON-PARENCHYMAL CELLS, AND METHODS FOR PREPARATION THEREOF THE UNIVERSITY OF TOKYO (JP) 2025-01-16 US disclosed
CN-119072542-A Maturation-promoting agent having ALK 5-inhibiting activity and CDK 8/19-inhibiting activity 千纸鹤治疗公司 2024-12-03 CN disclosed
CN-112867787-B Insulin producing cells 千纸鹤治疗公司 2024-11-22 CN disclosed
US-20240376435-A1 KIDNEY ORGANOID AND METHOD FOR PRODUCING SAME OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-11-14 US disclosed
CN-116829697-A Ripening agent 千纸鹤治疗公司 2023-09-29 CN disclosed
CN-116391028-A Ripening agent 千纸鹤治疗公司 2023-07-04 CN disclosed
CN-116355850-A Construction method and application of colorectal cancer organoids 中国医学科学院基础医学研究所 2023-06-30 CN disclosed
WO-2023033137-A1 KIDNEY ORGANOID AND METHOD FOR PRODUCING SAME 大塚製薬株式会社 2023-03-09 WO disclosed
EP-3246394-B1 METHOD FOR INDUCING DIFFERENTIATION OF CORNEAL EPITHELIAL CELLS FROM PLURIPOTENT STEM CELLS UNIV OSAKA (JP) 2022-11-23 EP disclosed
WO-2022107877-A1 MATURATION AGENT オリヅルセラピューティクス株式会社 2022-05-27 WO disclosed
EP-3990624-A1 ENHANCED DIFFERENTIATION OF BETA CELLS Vertex Pharmaceuticals Incorporated (US) 2022-05-04 EP disclosed
US-20220041990-A1 METHODS, COMPOSITIONS, AND KITS FOR PRODUCING SKELETAL MUSCLE STEM CELLS AND TREATING DISORDERS UNIV JOHNS HOPKINS (US) 2022-02-10 US disclosed
EP-3945827-A2 METHODS, COMPOSITIONS, AND KITS FOR PRODUCING SKELETAL MUSCLE STEM CELLS AND TREATING DISORDERS The Johns Hopkins University (US) 2022-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220041990-A1 METHODS, COMPOSITIONS, AND KITS FOR PRODUCING SKELETAL MUSCLE STEM CELLS AND TREATING DISORDERS TNNC1, CKMT1A; CKMT1B, MYLK2 ROCK2 2530/4885ROCK1 2099/4885PRKACA 1212/4885
US-20260009003-A1 MANUFACTURING OF THERAPEUTIC SATELLITE CELLS FOR TREATING MUSCULAR DYSTROPHY CAPNS1, CAPN1, CAPN2 ROCK2 3736/4885ROCK1 4110/4885PRKACA 3481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.